We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Amazon.com, Salesforce, Abbott Laboratories and Fossil Group
Read MoreHide Full Article
For Immediate Release
Chicago, IL – August 21, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Amazon.com, Inc. (AMZN - Free Report) , Salesforce, Inc. (CRM - Free Report) , Abbott Laboratories (ABT - Free Report) and Fossil Group, Inc. (FOSL - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Research Reports for Amazon, Salesforce and Abbott
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc., Salesforce, Inc. and Abbott Laboratories, as well as a micro-cap stock Fossil Group, Inc. The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens, attempting to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.
Shares of Amazon.com have gained +3% over the year-to-date period against the Zacks Internet - Commerce industry’s gain of +11.8%. The company reported strong second-quarter results with revenues and earnings beating estimates. Top-line gained from solid growth across North America, International, and AWS segments.
Strengthening its AWS services portfolio and its growing adoption rate contributed well to AWS performance which grew 17.5% to $30.8 billion. Ultrafast delivery services and expanding content portfolio were beneficial. Strengthening relationships with third-party sellers was a positive. Robust advertising business contributed well. Prime services showed robust momentum with 12% growth.
However, the stock fell 7% after-hours due to weaker Q3 operating income guidance of $15.5-20.5 billion and concerns about margin pressure from heavy AI investments totaling $100+ billion in capital expenditure plans.
Salesforce has underperformed the Zacks Computer - Software industry over the year-to-date period (-26.2% vs. +17.3%). The company is facing stiff competition and unfavorable currency fluctuations are concerns. Softening IT spending amid ongoing macroeconomic uncertainties may hurt its growth prospects.
Nevertheless, Salesforce is benefiting from a robust demand environment as customers are undergoing a major digital transformation. Its sustained focus on aligning products with customer needs is driving the top line. Continued deal wins in the international market are another growth driver. The buyout of Slack has positioned it as a leader in enterprise team collaboration and improved its competitive standing compared to Microsoft Teams.
Salesforce’s strategy of continuous expansion of generative AI offerings will help it tap the growing opportunities in the space. The Zacks analyst estimates suggest that Salesforce revenues are expected to witness a CAGR of 9.1% through fiscal 2025-2028.
Shares of Abbott have outperformed the Zacks Medical - Products industry over the past year (+22.3% vs. +6%). The company’s strong pipeline is opening up new growth opportunities, supporting the company’s positive momentum and strong growth outlook for 2025. Freestyle Libre, Lingo and Libre Rio CGM devices are on a great trajectory.
Alinity, the company’s next-generation suite of systems, is a key driver in the core lab diagnostics business. The company is optimistic about its latest progress with biosimilars and expects this to significantly boost EPD sales through 2025. Within Nutrition, despite softness in international pediatric arm, Abbott is regaining market share banking on strong Adult Nutrition business.
Yet, the significant runoff of COVID-19 testing-related sales is hurting Abbott’s Diagnostics growth. Headwinds such as tough macro conditions, tariffs and foreign exchange also add to the worry.
Fossil’s shares have outperformed the Zacks Retail - Apparel and Shoes industry over the year-to-date period (+86.9% vs. -12.7%). This microcap company with market capitalization of $169.96 million has strengthened its balance sheet via a $150 million revolver due 2030 and debt exchange extending maturities to 2029, reducing refinancing risk and enhancing liquidity.
Despite a 16% sales decline in Q2 2025, gross margins rose to 57.5% and adjusted operating income reached $4 million, reflecting cost discipline, reduced promotions and channel optimization. Management guides for further margin gains as SG&A savings and licensing efficiencies take hold. Digital-first strategies — including influencer-led campaigns and full-price e-commerce — are boosting traffic and profitability.
The turnaround plan targets $30 million in FY25 savings through supply chain, pricing and vendor initiatives. However, revenue contraction, weak demand in Europe/China, tariff headwinds and intense competition pose risks. Valuation remains compelling at 0.21X EV/sales and 1.27X P/B against industry/sector multiples.
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights Amazon.com, Salesforce, Abbott Laboratories and Fossil Group
For Immediate Release
Chicago, IL – August 21, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Amazon.com, Inc. (AMZN - Free Report) , Salesforce, Inc. (CRM - Free Report) , Abbott Laboratories (ABT - Free Report) and Fossil Group, Inc. (FOSL - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Research Reports for Amazon, Salesforce and Abbott
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc., Salesforce, Inc. and Abbott Laboratories, as well as a micro-cap stock Fossil Group, Inc. The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Ahead of Wall Street
The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens, attempting to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.
You can read today's AWS here >>> Rotation Continues on Big Morning for Retail Earnings
Today's Featured Research Reports
Shares of Amazon.com have gained +3% over the year-to-date period against the Zacks Internet - Commerce industry’s gain of +11.8%. The company reported strong second-quarter results with revenues and earnings beating estimates. Top-line gained from solid growth across North America, International, and AWS segments.
Strengthening its AWS services portfolio and its growing adoption rate contributed well to AWS performance which grew 17.5% to $30.8 billion. Ultrafast delivery services and expanding content portfolio were beneficial. Strengthening relationships with third-party sellers was a positive. Robust advertising business contributed well. Prime services showed robust momentum with 12% growth.
However, the stock fell 7% after-hours due to weaker Q3 operating income guidance of $15.5-20.5 billion and concerns about margin pressure from heavy AI investments totaling $100+ billion in capital expenditure plans.
(You can read the full research report on Amazon.com here >>>)
Salesforce has underperformed the Zacks Computer - Software industry over the year-to-date period (-26.2% vs. +17.3%). The company is facing stiff competition and unfavorable currency fluctuations are concerns. Softening IT spending amid ongoing macroeconomic uncertainties may hurt its growth prospects.
Nevertheless, Salesforce is benefiting from a robust demand environment as customers are undergoing a major digital transformation. Its sustained focus on aligning products with customer needs is driving the top line. Continued deal wins in the international market are another growth driver. The buyout of Slack has positioned it as a leader in enterprise team collaboration and improved its competitive standing compared to Microsoft Teams.
Salesforce’s strategy of continuous expansion of generative AI offerings will help it tap the growing opportunities in the space. The Zacks analyst estimates suggest that Salesforce revenues are expected to witness a CAGR of 9.1% through fiscal 2025-2028.
(You can read the full research report on Salesforce here >>>)
Shares of Abbott have outperformed the Zacks Medical - Products industry over the past year (+22.3% vs. +6%). The company’s strong pipeline is opening up new growth opportunities, supporting the company’s positive momentum and strong growth outlook for 2025. Freestyle Libre, Lingo and Libre Rio CGM devices are on a great trajectory.
Alinity, the company’s next-generation suite of systems, is a key driver in the core lab diagnostics business. The company is optimistic about its latest progress with biosimilars and expects this to significantly boost EPD sales through 2025. Within Nutrition, despite softness in international pediatric arm, Abbott is regaining market share banking on strong Adult Nutrition business.
Yet, the significant runoff of COVID-19 testing-related sales is hurting Abbott’s Diagnostics growth. Headwinds such as tough macro conditions, tariffs and foreign exchange also add to the worry.
(You can read the full research report on Abbott here >>>)
Fossil’s shares have outperformed the Zacks Retail - Apparel and Shoes industry over the year-to-date period (+86.9% vs. -12.7%). This microcap company with market capitalization of $169.96 million has strengthened its balance sheet via a $150 million revolver due 2030 and debt exchange extending maturities to 2029, reducing refinancing risk and enhancing liquidity.
Despite a 16% sales decline in Q2 2025, gross margins rose to 57.5% and adjusted operating income reached $4 million, reflecting cost discipline, reduced promotions and channel optimization. Management guides for further margin gains as SG&A savings and licensing efficiencies take hold. Digital-first strategies — including influencer-led campaigns and full-price e-commerce — are boosting traffic and profitability.
The turnaround plan targets $30 million in FY25 savings through supply chain, pricing and vendor initiatives. However, revenue contraction, weak demand in Europe/China, tariff headwinds and intense competition pose risks. Valuation remains compelling at 0.21X EV/sales and 1.27X P/B against industry/sector multiples.
(You can read the full research report on Fossil here >>>)
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can access their live picks without cost or obligation.
See Stocks Free >>
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.